Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Review Article

Potential Therapeutic Targets of Curcumin, Most Abundant Active Compound of Turmeric Spice: Role in the Management of Various Types of Cancer

Author(s): Saleh A. Almatroodi, Mansoor Ali Syed and Arshad Husain Rahmani*

Volume 16, Issue 1, 2021

Published on: 02 November, 2020

Page: [3 - 29] Pages: 27

DOI: 10.2174/1574892815999201102214602

Price: $65

Open Access Journals Promotions 2
Abstract

Background: Curcumin, an active compound of turmeric spice, is one of the most-studied natural compounds and has been widely recognized as a chemopreventive agent. Several molecular mechanisms have proven that curcumin and its analogs play a role in cancer prevention through modulating various cell signaling pathways as well as in the inhibition of the carcinogenesis process.

Objective: To study the potential role of curcumin in the management of various types of cancer through modulating cell signalling molecules based on available literature and recent patents.

Methods: A wide-ranging literature survey was performed based on Scopus, PubMed, PubMed Central, and Google scholar for the implication of curcumin in cancer management, along with a special emphasis on human clinical trials. Moreover, patents were searched through www.google.com/patents, www.freepatentsonline.com, and www.freshpatents.com.

Result: Recent studies based on cancer cells have proven that curcumin has potential effects against cancer cells as it prevents the growth of cancer and acts as a cancer therapeutic agent. Besides, curcumin exerted anti-cancer effects by inducing apoptosis, activating tumor suppressor genes, cell cycle arrest, inhibiting tumor angiogenesis, initiation, promotion, and progression stages of tumor. It was established that co-treatment of curcumin and anti-cancer drugs could induce apoptosis and also play a significant role in the suppression of the invasion and metastasis of cancer cells.

Conclusion: Accumulating evidences suggest that curcumin has the potential to inhibit cancer growth, induce apoptosis, and modulate various cell signaling pathway molecules. Well-designed clinical trials of curcumin based on human subjects are still needed to establish the bioavailability, mechanism of action, efficacy, and safe dose in the management of various cancers.

Keywords: Angiogenesis, apoptosis, cancer, cell cycle, cell signaling pathways, clinical trials, synergistic effect.

[1]
All cancers. 2018. Available from: http://gco.iarc.fr/today (Accessed on June 15, 2019).
[2]
Omran AR. The epidemiologic transition. A theory of the epidemiology of population change. Milbank Mem Fund Q 1971; 49(4): 509-38.
[http://dx.doi.org/10.2307/3349375] [PMID: 5155251]
[3]
Gersten O, Wilmoth JR. The cancer transition in Japan since 1951. Demogr Res 2002; 7: 271-306.
[http://dx.doi.org/10.4054/DemRes.2002.7.5]
[4]
Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends-an update. Cancer Epidemiol Biomarkers Prev 2016; 25(1): 16-27.
[http://dx.doi.org/10.1158/1055-9965.EPI-15-0578] [PMID: 26667886]
[5]
Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. Curcumin and cancer: An “old-age” disease with an “age-old” solution. Cancer Lett 2008; 267(1): 133-64.
[http://dx.doi.org/10.1016/j.canlet.2008.03.025] [PMID: 18462866]
[6]
Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008; 269(2): 199-225.
[http://dx.doi.org/10.1016/j.canlet.2008.03.009] [PMID: 18479807]
[7]
Ghasemi F, Shafiee M, Banikazemi Z, et al. Curcumin inhibits NF-kB and Wnt/β-catenin pathways in cervical cancer cells. Pathol Res Pract 2019; 215(10): 152556.
[http://dx.doi.org/10.1016/j.prp.2019.152556] [PMID: 31358480]
[8]
Lee SJ, Krauthauser C, Maduskuie V, Fawcett PT, Olson JM, Rajasekaran SA. Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo. BMC Cancer 2011; 11: 144.
[http://dx.doi.org/10.1186/1471-2407-11-144] [PMID: 21501498]
[9]
Spiller SE, Logsdon NJ, Deckard LA, Sontheimer H. Inhibition of nuclear factor kappa-B signaling reduces growth in medulloblastoma in vivo. BMC Cancer 2011; 11: 136.
[http://dx.doi.org/10.1186/1471-2407-11-136] [PMID: 21492457]
[10]
Choudhuri T, Pal S, Das T, Sa G. Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem 2005; 280(20): 20059-68.
[http://dx.doi.org/10.1074/jbc.M410670200] [PMID: 15738001]
[11]
Ravindran J, Prasad S, Aggarwal BB. Curcumin and cancer cells: How many ways can curry kill tumor cells selectively? AAPS J 2009; 11(3): 495-510.
[http://dx.doi.org/10.1208/s12248-009-9128-x] [PMID: 19590964]
[12]
Menon VP, Sudheer AR. Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol 2007; 595: 105-25.
[http://dx.doi.org/10.1007/978-0-387-46401-5_3] [PMID: 17569207]
[13]
Hewlings SJ, Kalman DS. Curcumin: A review of its effects on human health. Foods 2017; 6(10): 97.
[http://dx.doi.org/10.3390/foods6100092] [PMID: 29065496]
[14]
Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow? Lancet 2001; 357(9255): 539-45.
[http://dx.doi.org/10.1016/S0140-6736(00)04046-0] [PMID: 11229684]
[15]
Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420(6917): 860-7.
[http://dx.doi.org/10.1038/nature01322] [PMID: 12490959]
[16]
Schreiber H, Rowley DA. Inflammation and cancer. In: Gallin JI, Snyderman R, Eds. Inflammation: basic principles and clinical correlates. (3rd ed.). Philadelphia: Lippincott Williams & Wilkins In: 1999; pp. 1117-29.
[17]
Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 2004; 14(6): 433-9.
[http://dx.doi.org/10.1016/j.semcancer.2004.06.006] [PMID: 15489136]
[18]
Grivennikov SI, Karin M. Inflammation and oncogenesis: A vicious connection. Curr Opin Genet Dev 2010; 20(1): 65-71.
[http://dx.doi.org/10.1016/j.gde.2009.11.004] [PMID: 20036794]
[19]
Bachmeier BE, Mohrenz IV, Mirisola V, et al. Curcumin downregulates the inflammatory cytokines CXCL1 and -2 in breast cancer cells via NFkappaB. Carcinogenesis 2008; 29(4): 779-89.
[http://dx.doi.org/10.1093/carcin/bgm248] [PMID: 17999991]
[20]
Göbel C, Breitenbuecher F, Kalkavan H, et al. Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity. Cell Death Dis 2014; 5(5): e1568.
[http://dx.doi.org/10.1038/cddis.2014.531] [PMID: 25501829]
[21]
Surh YJ, Chun KS. Cancer chemopreventive effects of curcumin. Adv Exp Med Biol 2007; 595: 149-72.
[http://dx.doi.org/10.1007/978-0-387-46401-5_5] [PMID: 17569209]
[22]
Surh YJ, Chun KS, Cha HH, et al. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: Down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res 2001; 480-481(481): 243-68.
[http://dx.doi.org/10.1016/S0027-5107(01)00183-X] [PMID: 11506818]
[23]
Goel A, Boland CR, Chauhan DP. Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett 2001; 172(2): 111-8.
[http://dx.doi.org/10.1016/S0304-3835(01)00655-3] [PMID: 11566484]
[24]
Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome. Cancer Res 2000; 60(24): 6788-93.
[PMID: 11156366]
[25]
Das L, Vinayak M. Long term effect of curcumin in restoration of tumour suppressor p53 and phase-II antioxidant enzymes via activation of Nrf2 signalling and modulation of inflammation in prevention of cancer. PLoS One 2015; 10(4): e0124000.
[http://dx.doi.org/10.1371/journal.pone.0124000] [PMID: 25860911]
[26]
Roy S, Yu Y, Padhye SB, Sarkar FH, Majumdar AP. Difluorinated-curcumin (CDF) restores PTEN expression in colon cancer cells by down-regulating miR-21. PLoS One 2013; 8(7): e68543.
[http://dx.doi.org/10.1371/journal.pone.0068543] [PMID: 23894315]
[27]
Li W, Zhou Y, Yang J, Li H, Zhang H, Zheng P. Curcumin induces apoptotic cell death and protective autophagy in human gastric cancer cells. Oncol Rep 2017; 37(6): 3459-66.
[http://dx.doi.org/10.3892/or.2017.5637] [PMID: 28498433]
[28]
Fan H, Liang Y, Jiang B, et al. Curcumin inhibits intracellular fatty acid synthase and induces apoptosis in human breast cancer MDA-MB-231 cells. Oncol Rep 2016; 35(5): 2651-6.
[http://dx.doi.org/10.3892/or.2016.4682] [PMID: 26985864]
[29]
Yu J, Zhou X, He X, Dai M, Zhang Q. Yu J1. Curcumin induces apoptosis involving bax/bcl-2 in human hepatoma SMMC-7721 cells. Asian Pac J Cancer Prev 2011; 12(8): 1925-9.
[PMID: 22292626]
[30]
Gupta MK, Qin RY. Mechanism and its regulation of tumor-induced angiogenesis. World J Gastroenterol 2003; 9(6): 1144-55.
[http://dx.doi.org/10.3748/wjg.v9.i6.1144] [PMID: 12800214]
[31]
Fu Z, Chen X, Guan S, Yan Y, Lin H, Hua ZC. Curcumin inhibits angiogenesis and improves defective hematopoiesis induced by tumor-derived VEGF in tumor model through modulating VEGF-VEGFR2 signaling pathway. Oncotarget 2015; 6(23): 19469-82.
[http://dx.doi.org/10.18632/oncotarget.3625] [PMID: 26254223]
[32]
Yoysungnoen P, Wirachwong P, Bhattarakosol P, Niimi H, Patumraj S. Effects of curcumin on tumor angiogenesis and biomarkers, COX-2 and VEGF, in hepatocellular carcinoma cell-implanted nude mice. Clin Hemorheol Microcirc 2006; 34(1-2): 109-15.
[PMID: 16543625]
[33]
Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane). J Biol Chem 1995; 270(42): 24995-5000.
[http://dx.doi.org/10.1074/jbc.270.42.24995] [PMID: 7559628]
[34]
Kumar A, Dhawan S, Hardegen NJ, Aggarwal BB. Curcumin (Diferuloylmethane) inhibition of Tumor Necrosis Factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-kappaB activation. Biochem Pharmacol 1998; 55(6): 775-83.
[http://dx.doi.org/10.1016/S0006-2952(97)00557-1] [PMID: 9586949]
[35]
Liu JL, Pan YY, Chen O, et al. Curcumin inhibits MCF-7 cells by modulating the NF-κB signaling pathway. Oncol Lett 2017; 14(5): 5581-4.
[http://dx.doi.org/10.3892/ol.2017.6860] [PMID: 29142607]
[36]
Sun J, Han J, Zhao Y, Zhu Q, Hu J. Curcumin induces apoptosis in tumor necrosis factor-alpha-treated HaCaT cells. Int Immunopharmacol 2012; 13(2): 170-4.
[http://dx.doi.org/10.1016/j.intimp.2012.03.025] [PMID: 22498762]
[37]
Weir NM, Selvendiran K, Kutala VK, et al. Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biol Ther 2007; 6(2): 178-84.
[http://dx.doi.org/10.4161/cbt.6.2.3577] [PMID: 17218783]
[38]
Qiao Q, Jiang Y, Li G. Inhibition of the PI3K/AKT-NF-κB pathway with curcumin enhanced radiation-induced apoptosis in human Burkitt’s lymphoma. J Pharmacol Sci 2013; 121(4): 247-56.
[http://dx.doi.org/10.1254/jphs.12149FP] [PMID: 23603894]
[39]
Hussain AR, Al-Rasheed M, Manogaran PS, et al. Curcumin induces apoptosis via inhibition of PI3′-kinase/AKT pathway in acute T cell leukemias. Apoptosis 2006; 11(2): 245-54.
[http://dx.doi.org/10.1007/s10495-006-3392-3] [PMID: 16502262]
[40]
Kuttikrishnan S, Siveen KS, Prabhu KS, et al. Curcumin induces apoptotic cell death via inhibition of PI3-kinase/Akt pathway in b-precursor acute lymphoblastic leukemia. Front Oncol 2019; 9: 484.
[http://dx.doi.org/10.3389/fonc.2019.00484] [PMID: 31275848]
[41]
Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003; 101(3): 1053-62.
[http://dx.doi.org/10.1182/blood-2002-05-1320] [PMID: 12393461]
[42]
Dou H, Shen R, Tao J, et al. Curcumin suppresses the colon cancer proliferation by inhibiting Wnt/β-catenin pathways via miR-130a. Front Pharmacol 2017; 8: 877.
[http://dx.doi.org/10.3389/fphar.2017.00877] [PMID: 29225578]
[43]
Stuckey A. Breast cancer: Epidemiology and risk factors. Clin Obstet Gynecol 2011; 54(1): 96-102.
[http://dx.doi.org/10.1097/GRF.0b013e3182080056] [PMID: 21278508]
[44]
Zhou QM, Sun Y, Lu YY, Zhang H, Chen QL, Su SB. Curcumin reduces mitomycin C resistance in breast cancer stem cells by regulating Bcl-2 family-mediated apoptosis. Cancer Cell Int 2017; 17: 84.
[http://dx.doi.org/10.1186/s12935-017-0453-3] [PMID: 28959140]
[45]
Lv ZD, Liu XP, Zhao WJ, et al. Curcumin induces apoptosis in breast cancer cells and inhibits tumor growth in vitro and in vivo. Int J Clin Exp Pathol 2014; 7(6): 2818-24.
[PMID: 25031701]
[46]
Yan G, Graham K, Lanza-Jacoby S. Curcumin enhances the anticancer effects of trichostatin a in breast cancer cells. Mol Carcinog 2013; 52(5): 404-11.
[http://dx.doi.org/10.1002/mc.21875] [PMID: 22290509]
[47]
Hu S, Xu Y, Meng L, Huang L, Sun H. Curcumin inhibits proliferation and promotes apoptosis of breast cancer cells. Exp Ther Med 2018; 16(2): 1266-72.
[http://dx.doi.org/10.3892/etm.2018.6345] [PMID: 30116377]
[48]
Carroll CE, Ellersieck MR, Hyder SM. Curcumin inhibits MPA-induced secretion of VEGF from T47-D human breast cancer cells. Menopause 2008; 15(3): 570-4.
[http://dx.doi.org/10.1097/gme.0b013e31814fae5d] [PMID: 18467956]
[49]
Ke CS, Liu HS, Yen CH, et al. Curcumin-induced Aurora-A suppression not only causes mitotic defect and cell cycle arrest but also alters chemosensitivity to anticancer drugs. J Nutr Biochem 2014; 25(5): 526-39.
[http://dx.doi.org/10.1016/j.jnutbio.2014.01.003] [PMID: 24613085]
[50]
Chen B, Zhang Y, Wang Y, Rao J, Jiang X, Xu Z. Curcumin inhibits proliferation of breast cancer cells through Nrf2-mediated down-regulation of Fen1 expression. J Steroid Biochem Mol Biol 2014; 143: 11-8.
[http://dx.doi.org/10.1016/j.jsbmb.2014.01.009] [PMID: 24486718]
[51]
Bimonte S, Barbieri A, Palma G, et al. Dissecting the role of curcumin in tumour growth and angiogenesis in mouse model of human breast cancer. Bio Med Res Int 2015; 2015: 878134.
[http://dx.doi.org/10.1155/2015/878134] [PMID: 25879038]
[52]
Piantino CB, Salvadori FA, Ayres PP, et al. An evaluation of the anti-neoplastic activity of curcumin in prostate cancer cell lines. Int Braz J Urol 2009; 35(3): 354-60.
[http://dx.doi.org/10.1590/S1677-55382009000300012] [PMID: 19538771]
[53]
Dorai T, Cao YC, Dorai B, Buttyan R, Katz AE. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate 2001; 47(4): 293-303.
[http://dx.doi.org/10.1002/pros.1074] [PMID: 11398177]
[54]
Khor TO, Keum YS, Lin W, et al. Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice. Cancer Res 2006; 66(2): 613-21.
[http://dx.doi.org/10.1158/0008-5472.CAN-05-2708] [PMID: 16423986]
[55]
Schmidt KT, Figg WD. The potential role of curcumin in prostate cancer: The importance of optimizing pharmacokinetics in clinical studies. Transl Cancer Res 2016; 5(Suppl. 6): S1107-10.
[http://dx.doi.org/10.21037/tcr.2016.11.04] [PMID: 30613476]
[56]
Shankar S, Srivastava RK. Involvement of Bcl-2 family members, phosphatidylinositol 3′-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer. Int J Oncol 2007; 30(4): 905-18.
[http://dx.doi.org/10.3892/ijo.30.4.905] [PMID: 17332930]
[57]
Hong JH, Ahn KS, Bae E, Jeon SS, Choi HY. The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo. Prostate Cancer Prostatic Dis 2006; 9(2): 147-52.
[http://dx.doi.org/10.1038/sj.pcan.4500856] [PMID: 16389264]
[58]
Chaudhary LR, Hruska KA. Inhibition of cell survival signal protein kinase B/Akt by curcumin in human prostate cancer cells. J Cell Biochem 2003; 89(1): 1-5.
[http://dx.doi.org/10.1002/jcb.10495] [PMID: 12682902]
[59]
Rahmani AH, Almatroudi A, AlRumaihi F, Khan AA. Pharmacological and therapeutic potential of neem (Azadirachta indica). Pharmacogn Rev 2018; 12: 250.
[http://dx.doi.org/10.4103/phrev.phrev_8_18]
[60]
Almatroudi A, Alsahli MA, Alrumaihi F, Allemailem KS, Rahmani AH. Ginger: A novel strategy to battle cancer through modulating cell signalling pathways: A review. Curr Pharm Biotechnol 2019; 20(1): 5-16.
[http://dx.doi.org/10.2174/1389201020666190119142331] [PMID: 30659535]
[61]
Rahmani AH, Aldebasi YH, Srikar S, Khan AA, Aly SM. Aloe vera: Potential candidate in health management via modulation of biological activities. Pharmacogn Rev 2015; 9(18): 120-6.
[http://dx.doi.org/10.4103/0973-7847.162118] [PMID: 26392709]
[62]
Rahmani AH, Al Shabrmi FM, Allemailem KS, Aly SM, Khan MA. Implications of green tea and its constituents in the prevention of cancer via the modulation of cell signalling pathway. BioMed Res Int 2015; 2015: 925640.
[http://dx.doi.org/10.1155/2015/925640] [PMID: 25977926]
[63]
Rahmani AH, Alsahli MA, Aly SM, Khan MA, Aldebasi YH. Role of curcumin in disease prevention and treatment. Adv Biomed Res 2018; 7: 38.
[http://dx.doi.org/10.4103/abr.abr_147_16] [PMID: 29629341]
[64]
Almatroodi SA, Alsahli MA, Almatroudi A, Rahmani AH. Garlic and its active compounds: A potential candidate in the prevention of cancer by modulating various cell signalling pathways. Anticancer Agents Med Chem 2019; 19(11): 1314-24.
[http://dx.doi.org/10.2174/1871520619666190409100955] [PMID: 30963982]
[65]
Rahmani A, Alsahli M, Almatroodi S. Active constituents of pomegranates (Punicagranatum) as potential candidates in the management of health through modulation of biological activities. J Pharmacogn 2017; 9(5): 689-95.
[http://dx.doi.org/10.5530/pj.2017.5.109]
[66]
Zhen L, Fan D, Yi X, Cao X, Chen D, Wang L. Curcumin inhibits oral squamous cell carcinoma proliferation and invasion via EGFR signaling pathways. Int J Clin Exp Pathol 2014; 7(10): 6438-46.
[PMID: 25400722]
[67]
Ardito F, Perrone D, Giuliani M, Testa NF, Muzio LL. Effects of curcumin on squamous cell carcinoma of tongue: An in vitro study. Curr Top Med Chem 2018; 18(3): 233-43.
[http://dx.doi.org/10.2174/1568026618666180412153824] [PMID: 29651934]
[68]
Chen CF, Lu CC, Chiang JH, et al. Synergistic inhibitory effects of cetuximab and curcumin on human cisplatin-resistant oral cancer CAR cells through intrinsic apoptotic process. Oncol Lett 2018; 16(5): 6323-30.
[http://dx.doi.org/10.3892/ol.2018.9418] [PMID: 30333889]
[69]
Lee HM, Patel V, Shyur LF, Lee WL. Copper supplementation amplifies the anti-tumor effect of curcumin in oral cancer cells. Phytomedicine 2016; 23(12): 1535-44.
[http://dx.doi.org/10.1016/j.phymed.2016.09.005] [PMID: 27765374]
[70]
Bano N, Yadav M, Das BC. Differential inhibitory effects of curcumin between HPV+ve and HPV-ve oral cancer stem cells. Front Oncol 2018; 26(8): 412.
[71]
Xiao C, Wang L, Zhu L, Zhang C, Zhou J. Curcumin inhibits oral squamous cell carcinoma SCC-9 cells proliferation by regulating miR-9 expression. Biochem Biophys Res Commun 2014; 454(4): 576-80.
[http://dx.doi.org/10.1016/j.bbrc.2014.10.122] [PMID: 25450696]
[72]
Lin YC, Chen HW, Kuo YC, Chang YF, Lee YJ, Hwang JJ. Therapeutic efficacy evaluation of curcumin on human oral squamous cell carcinoma xenograft using multimodalities of molecular imaging. Am J Chin Med 2010; 38(2): 343-58.
[http://dx.doi.org/10.1142/S0192415X10007890] [PMID: 20387230]
[73]
Wang A, Wang J, Zhang S, Zhang H, Xu Z, Li X. Curcumin inhibits the development of non-small cell lung cancer by inhibiting autophagy and apoptosis. Exp Ther Med 2017; 14(5): 5075-80.
[http://dx.doi.org/10.3892/etm.2017.5172] [PMID: 29201217]
[74]
Xu X, Zhu Y. Curcumin inhibits human non-small cell lung cancer xenografts by targeting STAT3 pathway. Am J Transl Res 2017; 9(8): 3633-41.
[PMID: 28861154]
[75]
Tang L, Liu J, Zhu L, et al. Curcumin inhibits growth of human NCI-H292 lung squamous cell carcinoma cells by increasing FOXA2 expression. Front Pharmacol 2018; 9: 60.
[http://dx.doi.org/10.3389/fphar.2018.00060] [PMID: 29456509]
[76]
Tsai JR, Liu PL, Chen YH, et al. Curcumin inhibits Non-Small cell lung cancer cells metastasis through the adiponectin/NF-kappab/MMPs signaling pathway. PLoS One 2015; 10(12): e0144462.
[http://dx.doi.org/10.1371/journal.pone.0144462] [PMID: 26656720]
[77]
Zhao W, Wang Y, Wang Y, Gao N, Han Z, Yu H. Potential anti- cancer effect of curcumin in human lung squamous cell carcinoma. Thorac Cancer 2015; 6(4): 508-16.
[http://dx.doi.org/10.1111/1759-7714.12222] [PMID: 26273408]
[78]
Jiao D, Wang J, Lu W, et al. Curcumin inhibited HGF-induced EMT and angiogenesis through regulating c-Met dependent PI3K/Akt/mTOR signaling pathways in lung cancer. Mol Ther Oncolytics 2016; 3: 16018.
[http://dx.doi.org/10.1038/mto.2016.18] [PMID: 27525306]
[79]
Li X, Ma S, Yang P, et al. Anticancer effects of curcumin on nude mice bearing lung cancer A549 cell subsets SP and NSP cells. Oncol Lett 2018; 16(5): 6756-62.
[http://dx.doi.org/10.3892/ol.2018.9488] [PMID: 30405819]
[80]
Pongrakhananon V, Nimmannit U, Luanpitpong S, Rojanasakul Y, Chanvorachote P. Curcumin sensitizes non-small cell lung cancer cell anoikis through reactive oxygen species-mediated Bcl-2 downregulation. Apoptosis 2010; 15(5): 574-85.
[http://dx.doi.org/10.1007/s10495-010-0461-4] [PMID: 20127174]
[81]
Hu A, Huang JJ, Zhang JF, et al. Curcumin induces G2/M cell cycle arrest and apoptosis of head and neck squamous cell carcinoma in vitro and in vivo through ATM/Chk2/p53-dependent pathway. Oncotarget 2017; 8(31): 50747-60.
[http://dx.doi.org/10.18632/oncotarget.17096] [PMID: 28881600]
[82]
Zhu X, Zhu R. Curcumin suppresses the progression of laryngeal squamous cell carcinoma through the upregulation of miR-145 and inhibition of the PI3K/Akt/mTOR pathway. OncoTargets Ther 2018; 11: 3521-31.
[http://dx.doi.org/10.2147/OTT.S159236] [PMID: 29950857]
[83]
Mou S, Zhou Z, He Y, Liu F, Gong L. Curcumin inhibits cell proliferation and promotes apoptosis of laryngeal cancer cells through Bcl-2 and PI3K/Akt, and by upregulating miR-15a. Oncol Lett 2017; 14(4): 4937-42.
[http://dx.doi.org/10.3892/ol.2017.6739] [PMID: 29085504]
[84]
Xi Y, Gao H, Callaghan MU, et al. Induction of BCL2-Interacting killer, BIK, is mediated for anti-cancer activity of curcumin in human head and neck squamous cell carcinoma cells. J Cancer 2015; 6(4): 327-32.
[http://dx.doi.org/10.7150/jca.11185] [PMID: 25767602]
[85]
LoTempio MM, Veena MS, Steele HL, et al. Curcumin suppresses growth of head and neck squamous cell carcinoma. Clin Cancer Res 2005; 11(19 Pt 1): 6994-7002.
[http://dx.doi.org/10.1158/1078-0432.CCR-05-0301] [PMID: 16203793]
[86]
Hu A, Huang JJ, Li RL, et al. Curcumin as therapeutics for the treatment of head and neck squamous cell carcinoma by activating SIRT1. Sci Rep 2015; 5: 13429.
[http://dx.doi.org/10.1038/srep13429] [PMID: 26299580]
[87]
Subramaniam D, Ponnurangam S, Ramamoorthy P, et al. Curcumin induces cell death in esophageal cancer cells through modulating Notch signaling. PLoS One 2012; 7(2): e30590.
[http://dx.doi.org/10.1371/journal.pone.0030590] [PMID: 22363450]
[88]
Hartojo W, Silvers AL, Thomas DG, et al. Curcumin promotes apoptosis, increases chemosensitivity, and inhibits nuclear factor kappaB in esophageal adenocarcinoma. Transl Oncol 2010; 3(2): 99-108.
[http://dx.doi.org/10.1593/tlo.09235] [PMID: 20360934]
[89]
O’Sullivan-Coyne G, O’Sullivan GC, O’Donovan TR, Piwocka K, McKenna SL. Curcumin induces apoptosis-independent death in oesophageal cancer cells. Br J Cancer 2009; 101(9): 1585-95.
[http://dx.doi.org/10.1038/sj.bjc.6605308] [PMID: 19809435]
[90]
Ye F, Zhang GH, Guan BX, Xu XC. Suppression of esophageal cancer cell growth using curcumin, (-)-epigallocatechin-3-gallate and lovastatin. World J Gastroenterol 2012; 18(2): 126-35.
[http://dx.doi.org/10.3748/wjg.v18.i2.126] [PMID: 22253518]
[91]
Tian F, Zhang C, Tian W, Jiang Y, Zhang X. Comparison of the effect of p65 siRNA and curcumin in promoting apoptosis in esophageal squamous cell carcinoma cells and in nude mice. Oncol Rep 2012; 28(1): 232-40.
[http://dx.doi.org/10.3892/or.2012.1777] [PMID: 22552693]
[92]
Zheng BZ, Liu TD, Chen G, Zhang JX, Kang X. The effect of curcumin on cell adhesion of human esophageal cancer cell. Eur Rev Med Pharmacol Sci 2018; 22(2): 551-60.
[PMID: 29424917]
[93]
Rahmani AH, Khan AA, Babiker AY, Khan MA, Alzohairy MA. Therapeutic implications of ajwa dates (Phoenix dactylifera) in the inhibition of liver tissue alterations through the modulation of vascular endothelial growth factor and phosphatase, and tensin homolog gene. Phcog Res 2018; 10: 151-5.
[http://dx.doi.org/10.4103/pr.pr_119_17]
[94]
Aldebasi YH, Aly SM, Rahmani AH. Therapeutic implications of curcumin in the prevention of diabetic retinopathy via modulation of anti-oxidant activity and genetic pathways. Int J Physiol Pathophysiol Pharmacol 2013; 5(4): 194-202.
[PMID: 24379904]
[95]
Rahmani AH, Alzohairy MA, Khan MA, Aly SM. Therapeutic implications of black seed and its constituent thymoquinone in the prevention of cancer through inactivation and activation of molecular pathways. Evid Based Complement Alternat Med 2014; 2014: 724658.
[http://dx.doi.org/10.1155/2014/724658] [PMID: 24959190]
[96]
Chiablaem K, Lirdprapamongkol K, Keeratichamroen S, Surarit R, Svasti J. Curcumin suppresses vasculogenic mimicry capacity of hepatocellular carcinoma cells through STAT3 and PI3K/AKT inhibition. Anticancer Res 2014; 34(4): 1857-64.
[PMID: 24692720]
[97]
Lin LI, Ke YF, Ko YC, Lin JK. Curcumin inhibits SK-Hep-1 hepatocellular carcinoma cell invasion in vitro and suppresses matrix metalloproteinase-9 secretion. Oncology 1998; 55(4): 349-53.
[http://dx.doi.org/10.1159/000011876] [PMID: 9663426]
[98]
Wang S, Yu S, Shi W, et al. Curcumin inhibits the migration and invasion of mouse hepatoma HCA-F cells through down-regulating caveolin-1 expression and epidermal growth factor receptor signaling. IUBMB Life 2011; 63(9): 775-82.
[http://dx.doi.org/10.1002/iub.507] [PMID: 22362715]
[99]
Pan Z, Zhuang J, Ji C, Cai Z, Liao W, Huang Z. Curcumin inhibits hepatocellular carcinoma growth by targeting VEGF expression. Oncol Lett 2018; 15(4): 4821-6.
[http://dx.doi.org/10.3892/ol.2018.7988] [PMID: 29552121]
[100]
Zhou X, Su J, Feng S, et al. Antitumor activity of curcumin is involved in down-regulation of YAP/TAZ expression in pancreatic cancer cells. Oncotarget 2016; 7(48): 79076-88.
[http://dx.doi.org/10.18632/oncotarget.12596] [PMID: 27738325]
[101]
Bimonte S, Barbieri A, Palma G, Luciano A, Rea D, Arra C. Curcumin inhibits tumor growth and angiogenesis in an orthotopic mouse model of human pancreatic cancer. BioMed Res Int 2013; 2013: 810423.
[http://dx.doi.org/10.1155/2013/810423] [PMID: 24324975]
[102]
Zhang Y, Xue YB, Li H, Qiu D, Wang ZW, Tan SS. Inhibition of cell survival by curcumin is associated with downregulation of cell division cycle 20 (Cdc20) in pancreatic cancer cells. Nutrients 2017; 9(2): 109.
[http://dx.doi.org/10.3390/nu9020109] [PMID: 28165402]
[103]
Su J, Zhou X, Yin X, et al. The effects of curcumin on proliferation, apoptosis, invasion, and NEDD4 expression in pancreatic cancer. Biochem Pharmacol 2017; 140: 28-40.
[http://dx.doi.org/10.1016/j.bcp.2017.05.014] [PMID: 28535906]
[104]
Zhu Y, Bu S. Curcumin induces autophagy, apoptosis, and cell cycle arrest in human pancreatic cancer cells. Evid Based Complement Alternat Med 2017; 2017: 5787218.
[http://dx.doi.org/10.1155/2017/5787218] [PMID: 29081818]
[105]
Lu CH, Lin SH, Hsieh CH, Chen WT, Chao CY. Enhanced anticancer effects of low-dose curcumin with non-invasive pulsed electric field on PANC-1 cells. OncoTargets Ther 2018; 11: 4723-32.
[http://dx.doi.org/10.2147/OTT.S166264] [PMID: 30127620]
[106]
Sahu RP, Batra S, Srivastava SK. Activation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells. Br J Cancer 2009; 100(9): 1425-33.
[http://dx.doi.org/10.1038/sj.bjc.6605039] [PMID: 19401701]
[107]
Zhou S, Yao D, Guo L, Teng L. Curcumin suppresses gastric cancer by inhibiting gastrin-mediated acid secretion. FEBS Open Bio 2017; 7(8): 1078-84.
[http://dx.doi.org/10.1002/2211-5463.12237] [PMID: 28781948]
[108]
Da W, Zhang J, Zhang R, Zhu J. Curcumin inhibits the lymphangiogenesis of gastric cancer cells by inhibiton of HMGB1/VEGF-D signaling. Int J Immunopathol Pharmacol 2019; 33: 2058738419861600.
[http://dx.doi.org/10.1177/2058738419861600] [PMID: 31266378]
[109]
Liu G, Xiang T, Wu Q-F, Wang W-X. Curcumin suppresses the proliferation of gastric cancer cells by downregulating H19. Oncol Lett 2016; 12(6): 5156-62.
[http://dx.doi.org/10.3892/ol.2016.5354] [PMID: 28105222]
[110]
Liu X, Sun K, Song A, Zhang X, Zhang X, He X. Curcumin inhibits proliferation of gastric cancer cells by impairing ATP-sensitive potassium channel opening. World J Surg Oncol 2014; 12: 389.
[http://dx.doi.org/10.1186/1477-7819-12-389] [PMID: 25523120]
[111]
Gu X, Zhang Q, Zhang W, Zhu L. Curcumin inhibits liver metastasis of gastric cancer through reducing circulating tumor cells. Aging (Albany NY) 2019; 11(5): 1501-9.
[http://dx.doi.org/10.18632/aging.101848] [PMID: 30844765]
[112]
Johnson JJ, Mukhtar H. Curcumin for chemoprevention of colon cancer. Cancer Lett 2007; 255(2): 170-81.
[http://dx.doi.org/10.1016/j.canlet.2007.03.005] [PMID: 17448598]
[113]
Kanwar SS, Yu Y, Nautiyal J, et al. Difluorinated-curcumin (CDF): A novel curcumin analog is a potent inhibitor of colon cancer stem-like cells. Pharm Res 2011; 28(4): 827-38.
[http://dx.doi.org/10.1007/s11095-010-0336-y] [PMID: 21161336]
[114]
Su CC, Lin JG, Li TM, et al. Su CC1. Curcumin-induced apoptosis of human colon cancer colo 205 cells through the production of ROS, Ca2+ and the activation of caspase-3. Anticancer Res 2006; 26(6B): 4379-89.
[PMID: 17201158]
[115]
Song G, Mao YB, Cai QF, Yao LM, Ouyang GL, Bao SD. Curcumin induces human HT-29 colon adenocarcinoma cell apoptosis by activating p53 and regulating apoptosis-related protein expression. Braz J Med Biol Res 2005; 38(12): 1791-8.
[http://dx.doi.org/10.1590/S0100-879X2005001200007] [PMID: 16302093]
[116]
Li F, Chen X, Xu B, Zhou H. Li F1. Curcumin induces p53-independent necrosis in H1299 cells via a mitochondria-associated pathway. Mol Med Rep 2015; 12(5): 7806-14.
[http://dx.doi.org/10.3892/mmr.2015.4395] [PMID: 26460892]
[117]
Lev-Ari S, Strier L, Kazanov D, et al. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin Cancer Res 2005; 11(18): 6738-44.
[http://dx.doi.org/10.1158/1078-0432.CCR-05-0171] [PMID: 16166455]
[118]
Garcea G, Berry DP, Jones DJ, et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: Assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 2005; 14(1): 120-5.
[PMID: 15668484]
[119]
Liu TY, Tan ZJ, Jiang L, et al. Curcumin induces apoptosis in gallbladder carcinoma cell line GBC-SD cells. Cancer Cell Int 2013; 13(1): 64-10.
[http://dx.doi.org/10.1186/1475-2867-13-64] [PMID: 23802572]
[120]
Ono M, Higuchi T, Takeshima M, Chen C, Nakano S. Antiproliferative and apoptosis-inducing activity of curcumin against human gallbladder adenocarcinoma cells. Anticancer Res 2013; 33(5): 1861-6.
[PMID: 23645731]
[121]
Pandey P, Sayyed U, Tiwari R, Pathak N, Siddiqui MH, Bajpai P. Anticancer and apoptosis inducing effects of curcumin against gall bladder carcinoma. Int J Res Pharm Sci 2018; 9: 68-77.
[http://dx.doi.org/10.26452/ijrps.v9i1.1176]
[122]
Chen Q, Gao Q, Chen K, Wang Y, Chen L, Li XU. Curcumin suppresses migration and invasion of human endometrial carcinoma cells. Oncol Lett 2015; 10(3): 1297-302.
[http://dx.doi.org/10.3892/ol.2015.3478] [PMID: 26622667]
[123]
Xu H, Gong Z, Zhou S, et al. Liposomal curcumin targeting endometrial cancer through the NF-κB pathway. Cell Physiol Biochem 2018; 48(2): 569-82.
[http://dx.doi.org/10.1159/000491886] [PMID: 30021217]
[124]
Feng W, Yang CX, Zhang L, Fang Y, Yan M. Curcumin promotes the apoptosis of human endometrial carcinoma cells by downregulating the expression of androgen receptor through Wnt signal pathway. Eur J Gynaecol Oncol 2014; 35(6): 718-23.
[PMID: 25556280]
[125]
Liang YJ, Zhang HM, Wu YZ, Hao Q, Wang JD, Hu YL. Inhibiting effect of letrozole combined with curcumin on xenografted endometrial carcinoma growth in nude mice. Chin J Cancer 2010; 29(1): 9-14.
[http://dx.doi.org/10.5732/cjc.009.10440] [PMID: 20038303]
[126]
Zhao J, Zhao Y. Effects of curcumin on proliferation and apoptosis of human cervical carcinoma HeLa cells in vitro. Chin J Cancer Res 2004; 16: 225.
[http://dx.doi.org/10.1007/s11670-004-0032-8]
[127]
Xu F, Mu X, Zhao J. Effects of curcumin on invasion and metastasis in the human cervical cancer cells Caski. Chin J Cancer Res 2009; 21(2): 159-62.
[http://dx.doi.org/10.1007/s11670-009-0159-8]
[128]
Yoysungnoen-Chintana P, Bhattarakosol P, Patumraj S. Antitumor and antiangiogenic activities of curcumin in cervical cancer xenografts in nude mice. BioMed Res Int 2014; 2014: 817972.
[http://dx.doi.org/10.1155/2014/817972] [PMID: 24860830]
[129]
de Matos RPA, Calmon MF, Amantino CF, et al. Effect of curcumin-nanoemulsion associated with photodynamic therapy in cervical carcinoma cell lines. BioMed Res Int 2018; 2018: 4057959.
[http://dx.doi.org/10.1155/2018/4057959] [PMID: 29581972]
[130]
Yallapu MM, Maher DM, Sundram V, Bell MC, Jaggi M, Chauhan SC. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. J Ovarian Res 2010; 3: 11-0.
[http://dx.doi.org/10.1186/1757-2215-3-11] [PMID: 20429876]
[131]
Watson JL, Greenshields A, Hill R, et al. Curcumin-induced apoptosis in ovarian carcinoma cells is p53-independent and involves p38 mitogen-activated protein kinase activation and downregulation of Bcl-2 and survivin expression and Akt signaling. Mol Carcinog 2010; 49(1): 13-24.
[http://dx.doi.org/10.1002/mc.20571] [PMID: 19676105]
[132]
Zheng L, Tong Q, Wu C. Growth-inhibitory effects of curcumin on ovary cancer cells and its mechanisms. J Huazhong Univ Sci Technolog Med Sci 2004; 24(1): 55-8.
[http://dx.doi.org/10.1007/BF02830706] [PMID: 15165116]
[133]
Zheng LD, Tong QS, Wu CH. Growth inhibition and apoptosis inducing mechanisms of curcumin on human ovarian cancer cell line A2780. Chin J Integr Med 2006; 12(2): 126-31.
[http://dx.doi.org/10.1007/BF02857359] [PMID: 16800992]
[134]
Li W, Wang Y, Song Y, Xu L, Zhao J, Fang B. A preliminary study of the effect of curcumin on the expression of p53 protein in a human multiple myeloma cell line. Oncol Lett 2015; 9(4): 1719-24.
[http://dx.doi.org/10.3892/ol.2015.2946] [PMID: 25789029]
[135]
Sung B, Kunnumakkara AB, Sethi G, Anand P, Guha S, Aggarwal BB. Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther 2009; 8(4): 959-70.
[http://dx.doi.org/10.1158/1535-7163.MCT-08-0905] [PMID: 19372569]
[136]
Gomez-Bougie P, Halliez M, Maïga S, et al. Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups. Cancer Biol Ther 2015; 16(1): 60-5.
[http://dx.doi.org/10.4161/15384047.2014.986997] [PMID: 25517601]
[137]
Vadhan VS, Weber D, Giralt S, Alexanian, RThomas S. Curcumin downregulates NF-KB and related genes in patients with multiple myeloma: Results of a phase 1/11 study. Blood 2007; 110: 1177a.
[http://dx.doi.org/10.1182/blood.V110.11.1177.1177]
[138]
Sun C, Liu X, Chen Y, Liu F. Anticancer effect of curcumin on human B cell non-Hodgkin’s lymphoma. J Huazhong Univ Sci Technolog Med Sci 2005; 25(4): 404-7.
[http://dx.doi.org/10.1007/s11596-009-0402-z] [PMID: 16196288]
[139]
Qiao Q, Jiang Y, Li G. Curcumin enhances the response of non-Hodgkin’s lymphoma cells to ionizing radiation through further induction of cell cycle arrest at the G2/M phase and inhibition of mTOR phosphorylation. Oncol Rep 2013; 29(1): 380-6.
[http://dx.doi.org/10.3892/or.2012.2091] [PMID: 23117293]
[140]
Uddin S, Hussain AR, Manogaran PS, et al. Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma. Oncogene 2005; 24(47): 7022-30.
[http://dx.doi.org/10.1038/sj.onc.1208864] [PMID: 16044161]
[141]
Mackenzie GG, Queisser N, Wolfson ML, Fraga CG, Adamo AM, Oteiza PI. Curcumin induces cell-arrest and apoptosis in association with the inhibition of constitutively active NF-kappaB and STAT3 pathways in Hodgkin’s lymphoma cells. Int J Cancer 2008; 123(1): 56-65.
[http://dx.doi.org/10.1002/ijc.23477] [PMID: 18386790]
[142]
Das L, Vinayak M. Long-term effect of curcumin down-regulates expression of tumor necrosis factor-α and interleukin-6 via modulation of E26 transformation-specific protein and nuclear factor-κB transcription factors in livers of lymphoma bearing mice. Leuk Lymphoma 2014; 55(11): 2627-36.
[http://dx.doi.org/10.3109/10428194.2014.889824] [PMID: 24491024]
[143]
William BM, Goodrich A, Peng C, Li S. Curcumin inhibits proliferation and induces apoptosis of leukemic cells expressing wild- type or T315I-BCR-ABL and prolongs survival of mice with acute lymphoblastic leukemia. Hematology 2008; 13(6): 333-43.
[http://dx.doi.org/10.1179/102453308X343437] [PMID: 19055861]
[144]
Papież MA, Krzyściak W, Szade K, et al. Curcumin enhances the cytogenotoxic effect of etoposide in leukemia cells through induction of reactive oxygen species. Drug Des Devel Ther 2016; 10: 557-70.
[http://dx.doi.org/10.2147/DDDT.S92687] [PMID: 26893544]
[145]
Rajasingh J, Raikwar HP, Muthian G, Johnson C, Bright JJ. Curcumin induces growth-arrest and apoptosis in association with the inhibition of constitutively active JAK-STAT pathway in T cell leukemia. Biochem Biophys Res Commun 2006; 340(2): 359-68.
[http://dx.doi.org/10.1016/j.bbrc.2005.12.014] [PMID: 16364242]
[146]
Blasius R, Reuter S, Henry E, Dicato M, Diederich M. Curcumin regulates signal transducer and activator of transcription (STAT) expression in K562 cells. Biochem Pharmacol 2006; 72(11): 1547-54.
[http://dx.doi.org/10.1016/j.bcp.2006.07.029] [PMID: 16959222]
[147]
Ghosh AK, Kay NE, Secreto CR, Shanafelt TD. Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG. Clin Cancer Res 2009; 15(4): 1250-8.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-1511] [PMID: 19228728]
[148]
Herlyn M. Human melanoma: Development and progression. Cancer Metastasis Rev 1990; 9(2): 101-12.
[http://dx.doi.org/10.1007/BF00046337] [PMID: 2253310]
[149]
Singh RK, Gutman M, Radinsky R. Heterogeneity of cytokine and growth factor gene expression in human melanoma cells with different metastatic potentials. J Interferon Cytokine Res 1995; 15(1): 81-7.
[http://dx.doi.org/10.1089/jir.1995.15.81] [PMID: 7648437]
[150]
Srivastava SK, Bhardwaj A, Arora S, et al. Interleukin-8 is a key mediator of FKBP51-induced melanoma growth, angiogenesis and metastasis. Br J Cancer 2015; 112(11): 1772-81.
[http://dx.doi.org/10.1038/bjc.2015.154] [PMID: 25942396]
[151]
Wang B, Liu X, Teng Y, et al. Improving anti-melanoma effect of curcumin by biodegradable nanoparticles. Oncotarget 2017; 8(65): 108624-42.
[http://dx.doi.org/10.18632/oncotarget.20585] [PMID: 29312556]
[152]
Siwak DR, Shishodia S, Aggarwal BB, Kurzrock R. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer 2005; 104(4): 879-90.
[http://dx.doi.org/10.1002/cncr.21216] [PMID: 16007726]
[153]
Lu C, Song E, Hu DN, et al. Curcumin induces cell death in human uveal melanoma cells through mitochondrial pathway. Curr Eye Res 2010; 35(4): 352-60.
[http://dx.doi.org/10.3109/02713680903521944] [PMID: 20373902]
[154]
Bush JA, Cheung KJ Jr, Li G. Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53. Exp Cell Res 2001; 271(2): 305-14.
[http://dx.doi.org/10.1006/excr.2001.5381] [PMID: 11716543]
[155]
Zhang YP, Li YQ, Lv YT, Wang JM. Effect of curcumin on the proliferation, apoptosis, migration, and invasion of human melanoma A375 cells. Genet Mol Res 2015; 14(1): 1056-67.
[http://dx.doi.org/10.4238/2015.February.6.9] [PMID: 25730045]
[156]
Fang BM, Jiang JH, Zhang XW, Fan J, Li SS, Tong XM. Curcumin enhances bortezomib treatment of myeloma by inhibiting heat shock protein 90 expression. Trop J Pharm Res 2015; 14: 227-33.
[http://dx.doi.org/10.4314/tjpr.v14i2.6]
[157]
Yu T, Chen C, Sun Y, et al. ABT-737 sensitizes curcumin-induced anti-melanoma cell activity through facilitating mPTP death pathway. Biochem Biophys Res Commun 2015; 464(1): 286-91.
[http://dx.doi.org/10.1016/j.bbrc.2015.06.144] [PMID: 26116776]
[158]
Bill MA, Bakan C, Benson DM Jr, Fuchs J, Young G, Lesinski GB. Curcumin induces proapoptotic effects against human melanoma cells and modulates the cellular response to immunotherapeutic cytokines. Mol Cancer Ther 2009; 8(9): 2726-35.
[http://dx.doi.org/10.1158/1535-7163.MCT-09-0377] [PMID: 19723881]
[159]
Wang L, Shen Y, Song R, Sun Y, Xu J, Xu Q. An anticancer effect of curcumin mediated by down-regulating phosphatase of regenerating liver-3 expression on highly metastatic melanoma cells. Mol Pharmacol 2009; 76(6): 1238-45.
[http://dx.doi.org/10.1124/mol.109.059105] [PMID: 19779032]
[160]
Nabavi SM, Russo GL, Tedesco I, et al. Curcumin and melanoma: From chemistry to medicine. Nutr Cancer 2018; 70(2): 164-75.
[http://dx.doi.org/10.1080/01635581.2018.1412485] [PMID: 29300102]
[161]
Shi J, Zhang X, Shi T, Li H. Antitumor effects of curcumin in human bladder cancer in vitro. Oncol Lett 2017; 14(1): 1157-61.
[http://dx.doi.org/10.3892/ol.2017.6205] [PMID: 28693289]
[162]
Zhang L, Yang G, Zhang R, et al. Curcumin inhibits cell proliferation and motility via suppression of TROP2 in bladder cancer cells. Int J Oncol 2018; 53(2): 515-26.
[http://dx.doi.org/10.3892/ijo.2018.4423] [PMID: 29901071]
[163]
Sindhwani P, Hampton JA, Baig MM, Keck R, Selman SH. Curcumin prevents intravesical tumor implantation of the MBT-2 tumor cell line in C3H mice. J Urol 2001; 166(4): 1498-501.
[http://dx.doi.org/10.1016/S0022-5347(05)65819-3] [PMID: 11547120]
[164]
Kamat AM, Tharakan ST, Sung B, Aggarwal BB. Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors. Cancer Res 2009; 69(23): 8958-66.
[http://dx.doi.org/10.1158/0008-5472.CAN-09-2045] [PMID: 19903839]
[165]
Watanabe FT, Chade DC, Reis ST, et al. Curcumin, but not Prima-1, decreased tumor cell proliferation in the syngeneic murine orthotopic bladder tumor model. Clinics (São Paulo) 2011; 66(12): 2121-4.
[http://dx.doi.org/10.1590/S1807-59322011001200019] [PMID: 22189739]
[166]
Karmakar S, Banik NL, Patel SJ, Ray SK. Curcumin activated both receptor-mediated and mitochondria-mediated proteolytic pathways for apoptosis in human glioblastoma T98G cells. Neurosci Lett 2006; 407(1): 53-8.
[http://dx.doi.org/10.1016/j.neulet.2006.08.013] [PMID: 16949208]
[167]
Choi BH, Kim CG, Bae YS, Lim Y, Lee YH, Shin SY. p21 Waf1/Cip1 expression by curcumin in U-87MG human glioma cells: Role of early growth response-1 expression. Cancer Res 2008; 68(5): 1369-77.
[http://dx.doi.org/10.1158/0008-5472.CAN-07-5222] [PMID: 18316600]
[168]
Senft C, Polacin M, Priester M, Seifert V, Kögel D, Weissenberger J. The nontoxic natural compound Curcumin exerts anti-proliferative, anti-migratory, and anti-invasive properties against malignant gliomas. Cancer 2010; 10: 491-8.
[http://dx.doi.org/10.1186/1471-2407-10-491] [PMID: 20840775]
[169]
Dhandapani KM, Mahesh VB, Brann DW. Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors. J Neurochem 2007; 102(2): 522-38.
[http://dx.doi.org/10.1111/j.1471-4159.2007.04633.x] [PMID: 17596214]
[170]
Perna A, De Luca A, Adelfi L, Pasquale T, Varriale B, Esposito T. Effects of different extracts of curcumin on TPC1 papillary thyroid cancer cell line. BMC Complement Altern Med 2018; 18(1): 63.
[http://dx.doi.org/10.1186/s12906-018-2125-9] [PMID: 29448931]
[171]
Xu X, Qin J, Liu W. Curcumin inhibits the invasion of thyroid cancer cells via down-regulation of PI3K/Akt signaling pathway. Gene 2014; 546(2): 226-32.
[http://dx.doi.org/10.1016/j.gene.2014.06.006] [PMID: 24910117]
[172]
Zhang L, Cheng X, Xu S, Bao J, Yu H. Curcumin induces cell death of human papillary thyroid carcinoma BCPAP cells through endoplasmic reticulum stress. RSC Advances 2016; 6: 52905-12.
[http://dx.doi.org/10.1039/C6RA01515H]
[173]
Leow PC, Tian Q, Ong ZY, Yang Z, Ee PL. Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/β-catenin antagonists against human osteosarcoma cells. Invest New Drugs 2010; 28(6): 766-82.
[http://dx.doi.org/10.1007/s10637-009-9311-z] [PMID: 19730790]
[174]
Walters DK, Muff R, Langsam B, Born W, Fuchs B. Cytotoxic effects of curcumin on osteosarcoma cell lines. Invest New Drugs 2008; 26(4): 289-97.
[http://dx.doi.org/10.1007/s10637-007-9099-7] [PMID: 18071634]
[175]
Lee DS, Lee MK, Kim JH. Curcumin induces cell cycle arrest and apoptosis in human osteosarcoma (HOS) cells. Anticancer Res 2009; 29(12): 5039-44.
[PMID: 20044614]
[176]
Zhou C, Zhao XM, Li XF, et al. Curcumin inhibits AP-2γ-induced apoptosis in the human malignant testicular germ cells in vitro. Acta Pharmacol Sin 2013; 34(9): 1192-200.
[http://dx.doi.org/10.1038/aps.2013.38] [PMID: 23685957]
[177]
Cort A, Timur M, Ozdemir E, Ozben T. Effects of curcumin on bleomycin-induced apoptosis in human malignant testicular germ cells. J Physiol Biochem 2013; 69(2): 289-96.
[http://dx.doi.org/10.1007/s13105-012-0211-x] [PMID: 23001851]
[178]
Rutz J, Maxeiner S, Juengel E, et al. Growth and proliferation of renal cell carcinoma cells is blocked by low curcumin concentrations combined with visible light irradiation. Int J Mol Sci 2019; 20(6): E1464.
[http://dx.doi.org/10.3390/ijms20061464] [PMID: 30909499]
[179]
Zhang H, Xu W, Li B, et al. Curcumin promotes cell cycle arrest and inhibits survival of human renal cancer cells by negative modulation of the PI3K/AKT signaling pathway. Cell Biochem Biophys 2015; 73(3): 681-6.
[http://dx.doi.org/10.1007/s12013-015-0694-5] [PMID: 27259310]
[180]
Yu X, Zhong J, Yan L, et al. Curcumin exerts antitumor effects in retinoblastoma cells by regulating the JNK and p38 MAPK pathways. Int J Mol Med 2016; 38(3): 861-.
[http://dx.doi.org/10.3892/ijmm.2016.2676]
[181]
Li Y, Sun W, Han N, Zou Y, Yin D. Curcumin inhibits proliferation, migration, invasion and promotes apoptosis of retinoblastoma cell lines through modulation of miR-99a and JAK/STAT pathway. BMC Cancer 2018; 10(18): 1230.
[182]
Sreenivasan S, Thirumalai K, Krishnakumar S. Expression profile of genes regulated by curcumin in Y79 retinoblastoma cells. Nutr Cancer 2012; 64(4): 607-16.
[http://dx.doi.org/10.1080/01635581.2012.669875] [PMID: 22489823]
[183]
Alsaab H, Alzhrani RM, Kesharwani P, Sau S, Boddu SH, Iyer AK. Folate decorated nanomicelles loaded with a potent curcumin analogue for targeting retinoblastoma. Pharmaceutics 2017; 9(2): 15.
[http://dx.doi.org/10.3390/pharmaceutics9020015] [PMID: 28420213]
[184]
Ammon HP, Wahl MA. Pharmacology of Curcuma longa. Planta Med 1991; 57(1): 1-7.
[http://dx.doi.org/10.1055/s-2006-960004] [PMID: 2062949]
[185]
Ashrafizadeh M, Najafi M, Makvandi P, Zarrabi A, Farkhondeh T, Samarghandian S. Versatile role of curcumin and its derivatives in lung cancer therapy. J Cell Physiol 2020; 235(12): 9241-68.
[http://dx.doi.org/10.1002/jcp.29819] [PMID: 32519340]
[186]
Kanai M, Yoshimura K, Asada M, et al. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol 2011; 68(1): 157-64.
[http://dx.doi.org/10.1007/s00280-010-1470-2] [PMID: 20859741]
[187]
Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008; 14(14): 4491-9.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-0024] [PMID: 18628464]
[188]
Epelbaum R, Schaffer M, Vizel B, Badmaev V, Bar-Sela G. Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer 2010; 62(8): 1137-41.
[http://dx.doi.org/10.1080/01635581.2010.513802] [PMID: 21058202]
[189]
Durgaprasad S, Pai CG, Vasanthkumar, Alvres JF, Namitha S. A pilot study of the antioxidant effect of curcumin in tropical pancreatitis. Indian J Med Res 2005; 122(4): 315-8.
[PMID: 16394323]
[190]
Ide H, Tokiwa S, Sakamaki K, et al. Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen. Prostate 2010; 70(10): 1127-33.
[http://dx.doi.org/10.1002/pros.21147] [PMID: 20503397]
[191]
Bayet-Robert M, Kwiatkowski F, Leheurteur M, et al. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther 2010; 9(1): 8-14.
[http://dx.doi.org/10.4161/cbt.9.1.10392] [PMID: 19901561]
[192]
Sharma RA, McLelland HR, Hill KA, et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001; 7(7): 1894-900.
[PMID: 11448902]
[193]
Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance. Clin Cancer Res 2004; 10(20): 6847-54.
[http://dx.doi.org/10.1158/1078-0432.CCR-04-0744] [PMID: 15501961]
[194]
He ZY, Shi CB, Wen H, Li FL, Wang BL, Wang J. Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. Cancer Invest 2011; 29(3): 208-13.
[http://dx.doi.org/10.3109/07357907.2010.550592] [PMID: 21314329]
[195]
Carroll RE, Benya RE, Carroll RV, et al. Phase IIA clinical trial of curcumin for the prevention of colorectal neoplasia: Cancer. Prev Res (Phila) 2011; 4(3): 354-64.
[PMID: 21372035]
[196]
Cruz-Correa M, Shoskes DA, Sanchez P, et al. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 2006; 4(8): 1035-8.
[http://dx.doi.org/10.1016/j.cgh.2006.03.020] [PMID: 16757216]
[197]
Ghalaut VS, Sangwan L, Dahiya K, Ghalaut PS, Dhankhar R, Saharan R. Effect of imatinib therapy with and without turmeric powder on nitric oxide levels in chronic myeloid leukemia. J Oncol Pharm Pract 2012; 18(2): 186-90.
[http://dx.doi.org/10.1177/1078155211416530] [PMID: 21844132]
[198]
Vadhan-Raj S, Weber D, Wang M, et al. Curcumin downregulates NF-KB and related genes in patients with multiple myeloma: Results of a phase 1/2 study. Blood 2007; 110(11): 357a.
[http://dx.doi.org/10.1182/blood.V110.11.1177.1177]
[199]
Kim SG, Veena MS, Basak SK, et al. Curcumin treatment suppresses IKKβ kinase activity of salivary cells of patients with head and neck cancer: A pilot study. Clin Cancer Res 2011; 17(18): 5953-61.
[http://dx.doi.org/10.1158/1078-0432.CCR-11-1272] [PMID: 21821700]
[200]
Chainani-Wu N, Silverman S Jr, Reingold A, et al. A randomized, placebo-controlled, double-blind clinical trial of curcuminoids in oral lichen planus. Phytomedicine 2007; 14(7-8): 437-46.
[http://dx.doi.org/10.1016/j.phymed.2007.05.003] [PMID: 17604143]
[201]
Rai B, Kaur J, Jacobs R, Singh J. Possible action mechanism for curcumin in pre-cancerous lesions based on serum and salivary markers of oxidative stress. J Oral Sci 2010; 52(2): 251-6.
[http://dx.doi.org/10.2334/josnusd.52.251] [PMID: 20587949]
[202]
Chainani-Wu N, Madden E, Lozada-Nur F, Silverman S Jr. High- dose curcuminoids are efficacious in the reduction in symptoms and signs of oral lichen planus. J Am Acad Dermatol 2012; 66(5): 752-60.
[http://dx.doi.org/10.1016/j.jaad.2011.04.022] [PMID: 21907450]
[203]
Cruz-Correa M, Hylind LM, Marrero JH, et al. Efficacy and safety of curcumin in treatment of intestinal adenomas in patients with familial adenomatous polyposis. Gastroenterology 2018; 155(3): 668-73.
[http://dx.doi.org/10.1053/j.gastro.2018.05.031] [PMID: 29802852]
[204]
Panahi Y, Saadat A, Beiraghdar F, Sahebkar A. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: A randomized double-blind placebo-controlled trial. Phytother Res 2014; 28(10): 1461-7.
[http://dx.doi.org/10.1002/ptr.5149] [PMID: 24648302]
[205]
Demicheli R, Retsky MW, Hrushesky WJ, Baum M, Gukas ID. The effects of surgery on tumor growth: A century of investigations. Ann Oncol 2008; 19(11): 1821-8.
[http://dx.doi.org/10.1093/annonc/mdn386] [PMID: 18550576]
[206]
Rajput S, Mandal M. Antitumor promoting potential of selected phytochemicals derived from spices: A review. Eur J Cancer Prev 2012; 21(2): 205-15.
[http://dx.doi.org/10.1097/CEJ.0b013e32834a7f0c] [PMID: 21876437]
[207]
Banerjee S, Singh SK, Chowdhury I, Lillard JW Jr, Singh R. Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer. Front Biosci 2017; 9: 235-45.
[http://dx.doi.org/10.2741/e798] [PMID: 28199187]
[208]
Zhang H-H, Zhang Y, Cheng Y-N, et al. Metformin incombination with curcumin inhibits the growth, metastasis, and angiogenesis of hepatocellular carcinoma in vitro and in vivo. Mol Carcinog 2018; 57(1): 44-56.
[http://dx.doi.org/10.1002/mc.22718] [PMID: 28833603]
[209]
Shakibaei M, Buhrmann C, Kraehe P, Shayan P, Lueders C, Goel A. Curcumin chemosensitizes 5-fluorouracil resistant MMR-deficient human colon cancer cells in high density cultures. PLoS One 2014; 9(1): e85397.
[http://dx.doi.org/10.1371/journal.pone.0085397] [PMID: 24404205]
[210]
Masuelli L, Granato M, Benvenuto M, et al. Chloroquine supplementation increases the cytotoxic effect of curcumin against Her2/neu overexpressing breast cancer cells in vitro and in vivo in nude mice while counteracts it in immune competent mice. OncoImmunology 2017; 6(11): e1356151.
[http://dx.doi.org/10.1080/2162402X.2017.1356151] [PMID: 29147611]
[211]
Masuelli L, Benvenuto M, Di Stefano E, et al. Curcumin blocks autophagy and activates apoptosis of malignant mesothelioma cell lines and increases the survival of mice intraperitoneally transplanted with a malignant mesothelioma cell line. Oncotarget 2017; 8(21): 34405-22.
[http://dx.doi.org/10.18632/oncotarget.14907] [PMID: 28159921]
[212]
Zhou X, Wang W, Li P, et al. Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in inducing gastric cancer cell apoptosis both in vitro and in vivo. Oncol Res 2016; 23: 29-34.
[http://dx.doi.org/10.3727/096504015X14452563486011]
[213]
Masuelli L, Di Stefano E, Fantini M, et al. Resveratrol potentiates the in vitro and in vivo anti-tumoral effects of curcumin in head and neck carcinomas. Oncotarget 2014; 5(21): 10745-62.
[http://dx.doi.org/10.18632/oncotarget.2534] [PMID: 25296980]
[214]
Masuelli L, Benvenuto M, Fantini M, et al. Curcumin induces apoptosis in breast cancer cell lines and delays the growth of mammary tumors in neu transgenic mice. J Biol Regul Homeost Agents 2013; 27(1): 105-19.
[PMID: 23489691]
[215]
Masuelli L, Marzocchella L, Focaccetti C, et al. Resveratrol and diallyl disulfide enhance curcumin-induced sarcoma cell apoptosis. Front Biosci 2012; 17: 498-508.
[http://dx.doi.org/10.2741/3940] [PMID: 22201757]
[216]
Toden S, Okugawa Y, Jascur T, et al. Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer. Carcinogenesis 2015; 36(3): 355-67.
[http://dx.doi.org/10.1093/carcin/bgv006] [PMID: 25653233]
[217]
Wang BL, Shen YM, Zhang QW, et al. Codelivery of curcumin and doxorubicin by MPEG-PCL results in improved efficacy of systemically administered chemotherapy in mice with lung cancer. Int J Nanomedicine 2013; 8: 3521-31.
[PMID: 24101869]
[218]
Park BH, Lim JE, Jeon HG, et al. Curcumin potentiates antitumor activity of cisplatin in bladder cancer cell lines via ROS-mediated activation of ERK1/2. Oncotarget 2016; 7(39): 63870-86.
[http://dx.doi.org/10.18632/oncotarget.11563] [PMID: 27564099]
[219]
Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: Problems and promises. Mol Pharm 2007; 4(6): 807-18.
[http://dx.doi.org/10.1021/mp700113r] [PMID: 17999464]
[220]
Guorgui J, Wang R, Mattheolabakis G, Mackenzie GG. Curcumin formulated in solid lipid nanoparticles has enhanced efficacy in Hodgkin’s lymphoma in mice. Arch Biochem Biophys 2018; 648: 12-9.
[http://dx.doi.org/10.1016/j.abb.2018.04.012] [PMID: 29679536]
[221]
Guzman-Villanueva D, El-Sherbiny IM, Herrera-Ruiz D, Smyth HD. Design and in vitro evaluation of a new nano-microparticulate system for enhanced aqueous-phase solubility of curcumin. BioMed Res Int 2013; 2013: 724763.
[http://dx.doi.org/10.1155/2013/724763] [PMID: 23984402]
[222]
Gandapu U, Chaitanya RK, Kishore G, Reddy RC, Kondapi AK. Curcumin-loaded apotransferrin nanoparticles provide efficient cellular uptake and effectively inhibit HIV-1 replication in vitro. PLoS One 2011; 6(8): e23388.
[http://dx.doi.org/10.1371/journal.pone.0023388] [PMID: 21887247]
[223]
Kumar B, Yadav A, Hideg K, Kuppusamy P, Teknos TN, Kumar P. A novel curcumin analog (H-4073) enhances the therapeutic efficacy of cisplatin treatment in head and neck cancer. PLoS One 2014; 9(3): e93208.
[http://dx.doi.org/10.1371/journal.pone.0093208] [PMID: 24675768]
[224]
Khalil NM, do Nascimento TC, Casa DM, et al. Pharmacokinetics of curcumin-loaded PLGA and PLGA-PEG blend nanoparticles after oral administration in rats. Colloids Surf B Biointerfaces 2013; 101: 353-60.
[http://dx.doi.org/10.1016/j.colsurfb.2012.06.024] [PMID: 23010041]
[225]
Antony B, Merina B, Iyer VS, Judy N, Lennertz K, Joyal S. A pilot cross-over study to evaluate human oral bioavailability of BCM-95CG (Biocurcumax), A novel bioenhanced preparation of curcumin. Indian J Pharm Sci 2008; 70(4): 445-9.
[http://dx.doi.org/10.4103/0250-474X.44591] [PMID: 20046768]
[226]
Gopi S. A novel composition of curcumin with enhanced bioavailability. PCT/IB2014/063960. EP3035947, US20160151440, WO2015025263, 2016.
[227]
Jagt DLV, Deck LM, Abcouwer SF, Orlando RA, Royer RE, Waylon MW. Therapeutic curcumin derivatives. US20150011494, 2015.
[228]
Cuomo J, Appendino G, Dern AS, et al. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod 2011; 74(4): 664-9.
[http://dx.doi.org/10.1021/np1007262] [PMID: 21413691]
[229]
Chen Q. Therapeutic uses of curcumin analogs for treatment of prostate cancer. US20150017720, 2015.
[230]
Di Martino RMC, Bisi A, Rampa A, Gobbi S, Belluti F. Recent progress on curcumin-based therapeutics: A patent review (2012-2016). Part II: Curcumin derivatives in cancer and neurodegeneration. Expert Opin Ther Pat 2017; 27(8): 953-65.
[http://dx.doi.org/10.1080/13543776.2017.1339793] [PMID: 28597702]
[231]
Di Martino RM, Luppi B, Bisi A, et al. Recent progress on curcumin-based therapeutics: A patent review (2012-2016). Part I: Curcumin. Expert Opin Ther Pat 2017; 27(5): 579-90.
[http://dx.doi.org/10.1080/13543776.2017.1276566] [PMID: 28024125]
[232]
Razelle K, Lan L, Kapil M, Aggarwal B. Liposomal curcumin for treatment of cancer. US20160193159, 2016.
[233]
Franco C. Curcumin based compositions and methods of use thereof. US9782364, 2017.
[234]
Razelle K, Lan L. Liposomal curcumin for treatment of diseases. US20180318217, 2018.
[235]
Benny A. Composition to enhance the bioavailability of curcumin. US1051261, 2019.
[236]
Benny A. Composition to enhance the bioavailability of curcumin. US9861677, 2018.
[237]
Pattayil JA, Jayaprabha NK. Curcumin coated magnetite nanoparticles for biomedical applications. US9775919, 2017.
[238]
Gopi S, Jacob J, George R. Process for preparation of bioavailable white curcumin-a unique blend of hydrogenated curcuminoids. US10639285, 2020.
[239]
Giori A, Franceschi F. Phospholipid complexes of curcumin having improved bioavailability. US10603329, 2020.
[240]
Mewa S. Pharmaceutical compositions comprising hemp and turmeric to treat pain and inflammation. US20170042835, 2017.
[241]
Cardelli J, Dragoi A-M. Cancer treatment combination compositions, methods and uses. WO2017139644, 2017.
[242]
Sripathy R, Mandapati VNSRR, Gopaal A, et al. Novel highly bioavailable, water soluble and sustained release nanoformulations hydrophobic plant derived compounds and extracts. US20150072012, 2015.
[243]
Oguz O A, Ozgul M, Aydin M. Nanomicelles for the treatment of cancer. WO2016167730, 2016.
[244]
Sezgin Veliddin C, Bayraktar O. Preparation of curcumin- and piperine loaded biopolymer based nano-delivery systems using electrospray / coating techniques. EP3142702, 2018.
[245]
Benny A. Formulation of curcumin with enhanced bioavailability of curcumin and method of preparation and treatment thereof. EP2555787, 2017.
[246]
William H, Sita A, Hammer Robert P. Curcumin conjugates for treating and preventing cancers. US9221877, 2015.
[247]
Fawzy IM, Youssef KM, Abouzid KAM, Mohamed NS. Preparation of novel curcumin analogs with anticancer activity. WO2015067282, 2015.
[248]
Gokaraju GR, Gokaraju RR, Golakoti T, et al. Method of inhibition of beta-secretase by using bis-O-demethylcurcumin for the prevention, management and treatment of neurodegenerative diseases. WO2015186144, 2015.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy